Eli Lilly & Co. vs. Moleculin Biotech, Inc.
Eli Lilly & Co. (LLY) comes out ahead, leading on 2 of 2 compared factors.
Size & Scale
| LLY | MBRX | |
|---|---|---|
| Market Cap | $1.06 trillion | $15.06 million |
| Revenue (TTM) | $79.67 billion | — |
| Net Income (TTM) | $26.71 billion | — |
LLY leads on 1 of 1 size & scale factors.
Valuation
| LLY | MBRX | |
|---|---|---|
| P/E Ratio | 39.77 | — |
| Price / Book | 31.17 | — |
| Price / Sales | 13.26 | — |
LLY and MBRX split the valuation factors evenly.
Profitability
| LLY | MBRX | |
|---|---|---|
| Net Margin | 33.53% | — |
| Return on Equity | 78.84% | — |
LLY and MBRX split the profitability factors evenly.
Dividend
| LLY | MBRX | |
|---|---|---|
| Dividend Yield | 0.58% | — |
| Payout Ratio | 23.23 | — |
LLY and MBRX split the dividend factors evenly.
Risk & Sentiment
| LLY | MBRX | |
|---|---|---|
| Short Interest | 1.29% | 7.72% |
LLY leads on 1 of 1 risk & sentiment factors.
Dig deeper: LLY overview, LLY financials, MBRX overview, MBRX financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.